Company intelligence / Profile preview
Microbix Biosystems
Mississauga, Ontario, Canadamicrobix.com ↗
- Ownership
- Public · MBX
- Employees
- ~70
- Development stage
- Commercial
01
Overview
Microbix commercializes a broad portfolio of diagnostic antigens and quality assessment products used globally in clinical labs. Its QAPs™ line supports proficiency testing and assay validation across a wide range of infectious disease diagnostics. The company also owns Kinlytic® urokinase, a biologic thrombolytic drug previously approved in the US but currently seeking new commercialization partners[1][3][4].
- Therapeutic areas
- CardiovascularInfectious Diseases
- Modalities
- AntigenBiologicRecombinant protein
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Partners sought for Kinlytic® urokinase outlicensingmajor sales to clinical laboratory accreditation agencies
Beyond the preview
Go deeper on Microbix Biosystems.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Microbix Biosystems.